Eli Goldberger - ImmunoCellular Therapeutics Chairman Founder
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
Insider
Eli Goldberger is Chairman Founder of ImmunoCellular Therapeutics
| Age | 33 |
| Phone | 201 351 0605 |
| Web | https://www.eompharma.com |
ImmunoCellular Therapeutics Management Efficiency
The company has return on total asset (ROA) of (4.4045) % which means that it has lost $4.4045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (23.12) %, meaning that it created substantial loss on money invested by shareholders. ImmunoCellular Therapeutics' management efficiency ratios could be used to measure how well ImmunoCellular Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.ImmunoCellular Therapeutics currently holds 2.78 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. ImmunoCellular Therapeutics has a current ratio of 1.48, which is within standard range for the sector. Debt can assist ImmunoCellular Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, ImmunoCellular Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImmunoCellular Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImmunoCellular to invest in growth at high rates of return. When we think about ImmunoCellular Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| CPA CPA | Cellectar Biosciences | 60 | |
| Megan Knight | Longboard Pharmaceuticals | N/A | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Kevin Lind | Longboard Pharmaceuticals | 48 | |
| David Innes | Northwest Biotherapeutics | N/A | |
| Brian JD | Catalyst Pharmaceuticals | 60 | |
| Ruud Outersterp | Pharming Group NV | 59 | |
| MBA MD | Pharming Group NV | 63 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| CMA CPA | Catalyst Pharmaceuticals | 51 | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Bradley JD | Lumos Pharma | 45 | |
| Jean Davis | Northwest Biotherapeutics | 51 | |
| Stephen Toor | Pharming Group NV | 52 | |
| Lisa Miller | Lumos Pharma | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Steven JD | Longboard Pharmaceuticals | 59 | |
| Philip Schwartz | Catalyst Pharmaceuticals | 69 | |
| Marco Peters | Longboard Pharmaceuticals | N/A | |
| Jodi Parsons | Longboard Pharmaceuticals | N/A | |
| Gus Cardenas | Longboard Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 |
ImmunoCellular Therapeutics Leadership Team
Elected by the shareholders, the ImmunoCellular Therapeutics' board of directors comprises two types of representatives: ImmunoCellular Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoCellular. The board's role is to monitor ImmunoCellular Therapeutics' management team and ensure that shareholders' interests are well served. ImmunoCellular Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoCellular Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne CPA, CFO Treasurer | ||
| Shalom MD, Chief CoFounder | ||
| Eli Goldberger, Chairman Founder | ||
| BS MS, Pres CEO |
ImmunoCellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImmunoCellular Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Shares Owned By Insiders | 94.96 % | ||||
| Number Of Shares Shorted | 165.95 K | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Net Income | (5.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |